胆碱酯酶抑制剂对痴呆患者死亡率的影响:随机与非随机试验的系统综述
本系统综述纳入24项研究(12项随机对照试验、12项队列研究),共79,153例痴呆患者,平均随访6至120个月。胆碱酯酶抑制剂治疗与全因死亡率降低相关(未调整RR 0.74,95%CI 0.66-0.84;调整后HR 0.77,95%CI 0.70-0.84),心血管死亡率亦较低(未调整RR 0.61,95%CI 0.40-0.93;调整后HR 0.47,95%CI 0.32-0.68)。
要点
- 长期胆碱酯酶抑制剂治疗与痴呆患者全因死亡率降低相关(调整后HR 0.77,95%CI 0.70-0.84)。
- 心血管死亡率在胆碱酯酶抑制剂组亦较低(调整后HR 0.47,95%CI 0.32-0.68),但证据质量较低。
- 试验序贯分析显示全因死亡率结果确切,心血管死亡率结果尚未确切。
核心结论
- 有中等质量至高质量证据表明,长期胆碱酯酶抑制剂治疗与痴呆患者全因死亡率降低存在一致关联。
- 这些发现可能影响为痴呆患者处方胆碱酯酶抑制剂的决策。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、Cochrane CENTRAL、ClinicalTrials.gov和ICRTP自建库至2021年11月,并筛选综述、指南和纳入研究的参考文献。
- 纳入比较胆碱酯酶抑制剂与安慰剂或常规治疗、疗程6个月或以上、痴呆类型不限的随机对照试验和低偏倚风险的非随机对照研究。
- 共纳入24项研究(12项随机对照试验、12项队列研究),累计79,153例患者,平均随访6至120个月。
- 纳入患者痴呆类型:阿尔茨海默病13项研究、帕金森病痴呆1项、血管性痴呆1项、任何类型痴呆9项。
- 采用随机效应模型汇总全因死亡率和心血管死亡率数据,使用试验序贯分析评估信息量,遵循PRISMA指南。
主要发现
- 对照组患者汇总全因死亡率为15.1/100人年。
- 胆碱酯酶抑制剂治疗与较低的全因死亡率相关(未调整RR 0.74,95%CI 0.66-0.84;调整后HR 0.77,95%CI 0.70-0.84,中等质量至高质量证据)。
- 全因死亡率结果在随机与非随机研究间以及多项敏感性分析中保持一致。
- 按痴呆类型、年龄、单个药物或痴呆严重程度分组的亚组间未见差异。
- 心血管死亡率数据较少(3项随机对照试验、2项队列研究,9,182例患者,低质量至中等质量证据),胆碱酯酶抑制剂组亦较低(未调整RR 0.61,95%CI 0.40-0.93;调整后HR 0.47,95%CI 0.32-0.68)。
关键数值与推荐
- 全因死亡率:未调整RR 0.74(95%CI 0.66-0.84),调整后HR 0.77(95%CI 0.70-0.84),中等质量至高质量证据。
- 心血管死亡率:未调整RR 0.61(95%CI 0.40-0.93),调整后HR 0.47(95%CI 0.32-0.68),低质量至中等质量证据。
- 对照组患者汇总全因死亡率为15.1/100人年。
- 试验序贯分析显示全因死亡率结果确切,心血管死亡率结果不确切。
- 系统综述注册号:PROSPERO CRD42021254458(2021年6月11日)。
临床怎么用
- 原文结论指出,这些发现可能影响为痴呆患者处方胆碱酯酶抑制剂的决策。
局限性
- 心血管死亡率数据较少(3项随机对照试验、2项队列研究,9,182例患者),证据质量为低质量至中等质量。
- 试验序贯分析显示心血管死亡率结果不确切。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Cholinesterase inhibitors (ChEIs) have cardiovascular effects in addition to their neurologic activity and might alter mortality. We wanted to know whether treatment with ChEIs modifies mortality in patients with dementia. METHODS: We searched PubMed, Embase, Cochrane CENTRAL, ClinicalTrials.gov, and ICRTP, from their inception to November 2021, and screened bibliographies of reviews, guidelines, and included studies. We included randomized controlled trials (RCTs) and nonrandomized controlled studies at lower risk of bias comparing ChEI treatment with placebo or usual treatment, for 6 months or longer, in patients with dementia of any type. Two investigators independently assessed studies for inclusion, assessed their risk of bias, and extracted data using predefined forms. Any discordance between investigators was solved by discussion and consensus. Data on all-cause and cardiovascular mortality, measured as either crude death rates or multivariate adjusted hazard ratios (HRs), were pooled using a random-effect model. Information size achieved was assessed using trial sequential analysis (TSA). We followed Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. RESULTS: Twenty-four studies (12 RCTs, 12 cohorts, mean follow-up 6-120 months), cumulating 79,153 patients with Alzheimer (13 studies), Parkinson (1), vascular (1), or any type (9) dementia, fulfilled inclusion criteria. Pooled all-cause mortality in control patients was 15.1 per 100 person-years. Treatment with ChEIs was associated with lower all-cause mortality (unadjusted risk ratio [RR] 0.74, 95% CI 0.66-0.84; adjusted HR 0.77, 95% CI 0.70-0.84, moderate-quality to high-quality evidence). This result was consistent between randomized and nonrandomized studies and in several sensitivity analyses. No difference appeared between subgroups by type of dementia, age, individual drug, or dementia severity. Less data were available for cardiovascular mortality (3 RCTs, 2 cohorts, 9,182 patients, low-quality to moderate-quality evidence), which was also lower in patients treated with ChEIs (unadjusted RR 0.61, 95% CI 0.40-0.93, adjusted HR 0.47, 95% CI 0.32-0.68). In TSA analysis, the results for all-cause mortality were conclusive but not those for cardiovascular mortality. DISCUSSION: There is moderate-quality to high-quality evidence of a consistent association between long-term treatment with ChEIs and a reduction in all-cause mortality in patients with dementia. These findings may influence decisions to prescribe ChEIs in those patients. TRIAL REGISTRATION INFORMATION: This systematic review was registered in the PROSPERO international prospective register of systematic reviews with the number CRD42021254458 (June 11, 2021).
引用
- Truong C, Recto C, Lafont C, et al. Effect of Cholinesterase Inhibitors on Mortality in Patients With Dementia: A Systematic Review of Randomized and Nonrandomized Trials. Neurology. 2022. PMID: 36096687. doi:10.1212/WNL.0000000000201161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。